AMENDMENT NO. 2 TO EXECUTIVE COMPENSATION AGREEMENTFourth Stock Option Agreement • March 13th, 2017 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • Nevada
This Amendment No. 2 to Executive Compensation Agreement (“Amendment No. 2”), dated as of March 10, 2017, and effective as of January 1, 2017, is made by and between PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), and Kenneth L. Waggoner (“Executive”). The Company and the Executive are each referred to in this Amendment No. 2 as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment No. 2 shall have the meanings given to them in the Executive Compensation Agreement defined below.
FOURTH STOCK OPTION AGREEMENTFourth Stock Option Agreement • March 13th, 2017 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • Nevada
This Fourth Stock Option Agreement (“Agreement”) is made as of the 10th day of March, 2017 by and between PharmaCyte Biotech, Inc. (“Company”) and Gerald W. Crabtree (“Participant”).
